Cronos Group/$CRON
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cronos Group
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
- Ticker
- $CRON
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 610
- Headquarters
- Stayner, Canada
- Website
- thecronosgroup.com
Cronos Group Metrics
BasicAdvanced
$1.3B
23.42
$0.15
-
-
Price and volume
Market cap
$1.3B
52-week high
$3.91
52-week low
$2.28
Average daily volume
1.1M
Financial strength
Current ratio
12.713
Quick ratio
11.756
Long term debt to equity
0.001
Total debt to equity
0.001
Profitability
EBITDA (TTM)
25.454
Gross margin (TTM)
46.33%
Net profit margin (TTM)
28.04%
Operating margin (TTM)
5.12%
Effective tax rate (TTM)
-14.15%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
0.56%
Return on equity (TTM)
6.09%
Valuation
Price to earnings (TTM)
23.423
Price to revenue (TTM)
6.569
Price to book
1.75
Price to tangible book (TTM)
1.87
Price to free cash flow (TTM)
20.805
Free cash flow yield (TTM)
4.81%
Free cash flow per share (TTM)
0.174
Growth
Revenue change (TTM)
55.79%
Earnings per share change (TTM)
63.70%
3-year revenue growth (CAGR)
34.18%
10-year revenue growth (CAGR)
62.38%
3-year earnings per share growth (CAGR)
-18.70%
10-year earnings per share growth (CAGR)
42.63%
What the Analysts think about Cronos Group
Analyst ratings (Buy, Hold, Sell) for Cronos Group stock.
Analyst projections of the future price of Cronos Group stock.
Bulls say / Bears say
Cronos is growing quickly and turning more of that growth into operating earnings: Q3 revenue rose 73% on an organic, constant-currency basis, while gross profit and adjusted EBITDA both reached records. Its 50.9% quarterly gross margin and positive operating cash flow for the first nine months suggest the improvement is not just on paper. (Cronos Group)
Spinach is gaining share in Canada rather than relying on a rising market: its branded retail sales grew 41% year on year against industry growth of 1%. It held the top spot in vapes and edibles, supporting the case that product launches and brand strength can sustain growth. (Cronos Group)
Cronos is building growth beyond Canada, with Israel recording an eleventh straight quarter of record revenue and sales outside Israel rising sharply, led by Germany. Its roughly $843 million in cash, investments and interest-bearing deposits gives it room to fund expansion, including its newly completed CanAdelaar acquisition in the Netherlands. (Cronos Group)
Cronos’s Israeli growth carries a material regulatory overhang: a renewed anti-dumping investigation could lead to duties or import restrictions, putting sales and margins at risk. The company also flags the regional conflict as a possible disruption to its people, facilities and operations. (Cronos Group)
Recent growth may be uneven: management warned that Canadian provincial orders can soften seasonally and international shipments can swing with export-permit timing. It also said margins can vary with product mix, seasonality and price compression, making one strong quarter a shaky guide to future results. (StockAnalysis)
Rapid sales growth did not translate into higher year-on-year net income in Q3: net income fell to $17.8 million from $28.3 million. Higher operating costs and lower other income offset much of the stronger gross profit, so the company still needs to show that its operating gains can deliver steadier bottom-line growth. (Cronos Group)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
Cronos Group Financial Performance
Revenues and expenses
Cronos Group Earnings Performance
Company profitability
Upcoming events
No upcoming events
Cronos Group News
AllArticlesVideos
Funds containing Cronos Group
Fund name | Fund size | $CRON weighting |
|---|---|---|
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.01% |
SPDR MSCI All Country World IM€SPYI | $7.7B | 0.00% |
iShares MSCI World Small Cap€IUSN | $9B | 0.00% |
iShares MSCI World Small Cap$WSML | $9B | 0.00% |
iShares MSCI World Small Cap£WLDS | $9B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.